Revolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret A. Horn sold 4,329 shares of Revolution Medicines stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $196,536.60. Following the completion of the sale, the chief operating officer now owns 127,991 shares of the company’s stock, valued at $5,810,791.40. This trade represents a 3.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Revolution Medicines Price Performance

NASDAQ RVMD traded down $2.16 on Wednesday, reaching $43.00. The company had a trading volume of 1,019,225 shares, compared to its average volume of 1,392,216. The firm has a market capitalization of $7.23 billion, a PE ratio of -11.98 and a beta of 1.40. The firm has a 50-day moving average of $52.23 and a 200-day moving average of $46.05. Revolution Medicines, Inc. has a 1 year low of $25.60 and a 1 year high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). During the same quarter in the previous year, the firm earned ($0.99) earnings per share. As a group, sell-side analysts expect that Revolution Medicines, Inc. will post -3.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on RVMD shares. Oppenheimer boosted their target price on shares of Revolution Medicines from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, October 28th. JPMorgan Chase & Co. upped their price objective on Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a report on Tuesday, December 3rd. Barclays increased their target price on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, September 27th. Needham & Company LLC reissued a “buy” rating and set a $68.00 price target on shares of Revolution Medicines in a research report on Tuesday, December 3rd. Finally, Guggenheim raised their price objective on Revolution Medicines from $82.00 to $87.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and an average price target of $63.67.

Institutional Trading of Revolution Medicines

A number of hedge funds have recently made changes to their positions in the stock. Citigroup Inc. raised its holdings in Revolution Medicines by 29.5% in the third quarter. Citigroup Inc. now owns 117,938 shares of the company’s stock valued at $5,348,000 after acquiring an additional 26,871 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $801,000. State Street Corp lifted its position in shares of Revolution Medicines by 4.1% during the third quarter. State Street Corp now owns 5,279,584 shares of the company’s stock worth $239,429,000 after purchasing an additional 208,516 shares during the last quarter. Barclays PLC grew its stake in Revolution Medicines by 187.1% in the third quarter. Barclays PLC now owns 294,664 shares of the company’s stock worth $13,362,000 after purchasing an additional 192,021 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Revolution Medicines by 58.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,763,117 shares of the company’s stock worth $79,957,000 after purchasing an additional 653,433 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.